LivaNova (NASDAQ:LIVN) Receives Buy Rating from Mizuho

Mizuho reaffirmed their buy rating on shares of LivaNova (NASDAQ:LIVN) in a research note issued to investors on Wednesday morning, Benzinga reports. Mizuho currently has a $75.00 price target on the stock.

Several other analysts have also recently commented on LIVN. Needham & Company LLC reiterated a buy rating and issued a $72.00 price objective on shares of LivaNova in a research note on Wednesday, March 20th. Robert W. Baird raised their price objective on shares of LivaNova from $56.00 to $62.00 and gave the company a neutral rating in a research note on Thursday, February 22nd. Finally, Barclays raised their price objective on shares of LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a research note on Monday, February 26th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $64.40.

LivaNova Stock Up 2.7 %

LIVN stock opened at $55.87 on Wednesday. LivaNova has a one year low of $41.87 and a one year high of $59.86. The stock has a market capitalization of $3.01 billion, a PE ratio of 174.60 and a beta of 0.89. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.51 and a current ratio of 2.95. The company has a fifty day moving average of $52.03 and a 200-day moving average of $50.61.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.77 by $0.10. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The firm had revenue of $310.10 million during the quarter, compared to analysts’ expectations of $287.65 million. During the same quarter last year, the business earned $0.81 earnings per share. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. As a group, analysts expect that LivaNova will post 3.01 EPS for the current year.

Hedge Funds Weigh In On LivaNova

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new position in LivaNova during the second quarter worth about $46,000. Headlands Technologies LLC purchased a new stake in shares of LivaNova during the third quarter worth about $72,000. Point72 Middle East FZE purchased a new stake in shares of LivaNova during the fourth quarter worth about $72,000. Picton Mahoney Asset Management purchased a new stake in shares of LivaNova during the third quarter worth about $91,000. Finally, US Bancorp DE grew its holdings in shares of LivaNova by 12.4% during the second quarter. US Bancorp DE now owns 2,069 shares of the company’s stock worth $106,000 after buying an additional 229 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.